rs72835417

This variant is located in the B4GALNT2 gene.

GWAS Catalog Trait Associations (10)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

uromodulin measurement

Allele A
OR 0.17
p 9.0e-237
N 47,745
Large GWAS
European
Allele A
OR 0.22
p 2.0e-22
N 13,985
Large GWAS
multi-ancestry

HEPACAM family member 2 measurement

Allele A
OR 0.18
p 2.0e-137
N 47,745
Large GWAS
European

receptor tyrosine-protein kinase erbb-4 measurement

Allele A
OR 0.12
p 3.0e-51
N 47,745
Large GWAS
European

protein kinase C-binding protein NELL1 measurement

Allele A
OR 0.11
p 3.0e-45
N 47,745
Large GWAS
European

tumor-associated calcium signal transducer 2 measurement

Allele A
OR 0.06
p 1.0e-22
N 47,745
Large GWAS
European

sex hormone-binding globulin measurement

Sinnott-Armstrong N et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nature Genetics 53(2):185-194 (2021)
Allele A
OR 0.04
p 6.0e-21
N 322,484
Major Consortium StudyLarge GWAS
multi-ancestry

level of carbonic anhydrase 12 in blood serum

Allele A
OR 0.07
p 3.0e-17
N 47,745
Large GWAS
European

Ly6/PLAUR domain-containing protein 3 measurement

Allele A
OR 0.05
p 1.0e-11
N 47,745
Large GWAS
European

ClinVar annotation

Benign★★★
4 submitters2 publications

not provided; Uterine carcinosarcoma; Thymoma; Cholangiocarcinoma; Nonpapillary renal cell carcinoma; BLOOD GROUP, SID SYSTEM; Colorectal cancer

View on ClinVar →

About B4GALNT2

B4GALNT2 catalyzes the last step in the biosynthesis of the human Sd(a) antigen through the addition of an N-acetylgalactosamine residue via a beta-1,4 linkage to a subterminal galactose residue substituted with an alpha-2,3-linked sialic acid. B4GALNT2 also catalyzes the last step in the biosynthesis of the Cad antigen (Montiel et al., 2003 [PubMed 12678917]).[supplied by OMIM, Mar 2008]

View all B4GALNT2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…